Alphavirus-based vaccines

Viruses

Volumn 6, Issue 6, 2014, Pages 2392-2415

  Lundstrom, Kenneth ^a  

^a PanTherapeutics ^*  (Switzerland)

Author keywords

Alphaviruses; Clinical trials; DNA vaccines; Naked RNA; Protection against lethal virus challenges; Recombinant particles; Tumor protection; Vaccines

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN E2; HEMAGGLUTININ; INTERLEUKIN 4; PEPTIDES AND PROTEINS; TUMOR ANTIGEN; TYROSINE RELATED PROTEIN 2; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; CANCER VACCINE; DNA VACCINE;

ALPHA VIRUS; BACILLUS ANTHRACIS; CYTOMEGALOVIRUS; DNA REPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C VIRUS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; ALPHAVIRUS INFECTIONS; ANIMAL; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETICS; IMMUNOLOGY;

ALPHAVIRUS; ALPHAVIRUS INFECTIONS; ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HUMANS; VACCINES, DNA; VIRAL VACCINES;

EID: 84902602849     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v6062392     Document Type: Review

References (126)

1. Strauss, J.H.; Strauss, E.G. The Alphaviruses: Gene Expression, Replication and Evolution. Micobiol. Rev. 1994, 58, 491-562.
2. Kelvin, A.A. Outbreak of Chikungunya in the Republic of Congo and the global picture. J. Infect. Dev. Countries 2011, 5, 441-444.
3. Mathiot, C.C.; Grimaud, G.; Garry, P. An outbreak of Semliki Forest virus infections in Central African Republic. Am. J. Trop. Med. Hyg. 1990, 42, 386-393.
4. Weaver, S.C.; Salas, R.; Rico-Hesse, R. Remergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet 1996, 348, 436-440.
5. Liljeström, P.; Garoff, H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology 1991, 9, 1356-1361.
6. Xiong, C.; Levis, R.; Shen, P.; Schlesinger, S.; Rice, C.M.; Huang, H.V. Sindbis virus: An efficient, broad host range vector for gene expression in animal cells. Science 1989, 243, 1188-1191.
7. Davis, N.L.; Brown, K.W.; Johnston, R.E. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant. Virology 1989, 171, 189-204.
8. Smerdou, C.; Liljeström, P. Two-helper RNA system for production of recombinant Semliki Forest virus particles. J. Virol. 1999, 73, 1092-1098.
9. Lundstrom, K.; Schweizer, C.; Rotmann, D.; Hermann, D.; Schneider, E.M. Semliki Forest virus vectors: efficient vehicles for in vitro and in vivo gene delivery. FEBS Lett. 2001, 504, 99-103.
10. Lundstrom, K. Semliki Forest virus vectors for rapid and high-level expression of integral membrane proteins. Biochim. Biophys. Acta 2003, 1610, 90-96.
11. Ehrengruber, M.U.; Lundstrom, K.; Schweitzer, C.; Heuss, C.; Schlesinger, S.; Gähwiler, B.H. Recombinant Semliki Forest virus and Sindbis virus infect efficiently neurons in hippocampal slice cultures. Proc. Natl. Acad. Sci. USA 1999, 96, 7041-7046.
12. Lundstrom, K.; Richards, J.G.; Pink, J.R.; Jenck, F. Efficient in vivo expression of a reporter gene in rat brain after injection of recombinant replication-deficient Semliki Forest virus. Gene Ther. Mol. Biol. 1999, 3, 15-23.
13. Lundstrom, K. Alphavirus vectors for vaccine production and gene therapy. Exp. Rev. Vacc. 2003, 2, 447-459.
14. Tonkin, D.R.; Whitmore, R.; Johnston, R.E.; Barro, M. Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replication particles. Vaccine 2012, 30, 4532-4542.
15. Malone, J.G.; Berglund, P.J.; Liljestrom, P.; Rhodes, G.H.; Malone, R.W. Mucosal immune responses associated with polynucleotide vaccination. Behring Inst. Mitt. 1997, 98, 63-72.
16. Schultz-Cherry, S.; Dybing, J.K.; Davis, N.L.; Williamson, C.; Suarez, D.L.; Johnston, R.; Perdue, M.L. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects against lethal infection with Hong Kong-origin H5N1 viruses. Virology 2000, 278, 55-59.
17. Brand, D.; Lemiale, F.; Turbica, I.; Buzelay, L.; Brunet, S.; Branet, F. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. AIDS Res. Hum. Retroviruses 1998, 14, 1369-1377.
18. Giraud, A.; Ataman-Onal, Y.; Battail, N.; Piga, N.; Brand, D.; Mandrand, B.; Verrier, B. Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. J. Virol. Methods 1999, 79, 75-84.
19. Caley, I.J.; Betts, M.R.; Irlbeck, D.M.; Davis, N.L.; Swanstrom, R.; Frelinger, J.A.; Johnston, R.E. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 1997, 71, 3031-3038.
20. Bosworth, B.; Erdman, M.M.; Stine, D.L.; Harris, I.; Irwin, C.; Jens, M.; Loynachan, A.; Kamrud, K.; Harris, D.L. Replicon particle vaccine protects swine against influenza. Comp. Immunol. Microbiol. Infect. Dis. 2010, 33, e99-e103.
21. Wilson, J.A.; Hart, M.K. Protection from Ebola virus mediated by cytotoxic T-lymphocytes specific for the viral nucleoprotein. J. Virol. 2001, 75, 2660-2664.
22. Pushko, P.; Bray, M.; Ludwig, G.V.; Parker, M.; Schmaljohn, A.; Sanchez, A.; Jahrling, P.B.; Smith, J.F. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000, 19, 142-153.
23. Loy, J.D.; Grander, J.; Mogler, M.; Vander Veen, R.; Ridpath, J; Harris, D.H.; Kamrud, K. Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle. Virol. J. 2013, 10, e35.
24. Reddy, J.R.; Kwang, J.; Varthakavi, V.; Lechtenberg, K.F.; Minocha, H.C. Semiliki forest virus vector carrying the bovine viral diarrhea virus NS3 (p80) cDNA induced immune responses in mice and expressed BVDV protein in mammalian cells. Comp. Immunol. Microbiol. Infect. Dis. 1999, 22, 231-246.
25. Bernstein, D.I.; Reap, E.A.; Katen, K.; Watson, A.; Smith, K.; Norberg, P.; Olmsted, R.A.; Hoeper, A.; Morris, J.; Negri, S. et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28, 484-493.
26. Sun, Y.; Li, N.; Li, H.Y.; Li, M.; Qiu, H.J. Enhanced immunity against classical swine fever in pigs induced by prime-boost immunization using an alphavirus replicon-vectored DNA vaccine and a recombinant adenovirus. Vet. Immunol. Immunopathol. 2010, 137, 20-27.
27. White, L.J.; Sariol, C.A.; Mattocks, M.D.; Wahala, M.P.B.W.; Yingsiwaphat, V.; Collier, M.L.; Whitley, J.; Mikkelsen, R.; Rodriguez, I.V.; Martinez, M.I. et al. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J. Virol. 2013, 87, 3409-3424.
28. Wilson, J.A.; Bray, M.; Bakken, R.; Hart, M.K. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001, 286, 384-390.
29. Driver, D.A.; Latham, E.M.; Polo, J.M.; Belli, B.A.; Banks, T.A.; Chada, S.; Brumm, D.; Chang, S.M.; Mento, S.J.; Dolly, D.J. et al. Layered amplification of gene expression with a DNA gene delivery system. Ann. N. Y. Acad. Sci. 1995, 772, 261-264.
30. Vidalin, O.; Fournillier, A.; Renard, N.; Chen, M.; Depla, E.; Boucreux, D.; Brinster, C.; Baumert, T.; Nakano, I.; Fukuda, Y. et al. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens. Virology 2000, 276, 259-270.
31. Brinster, C.; Chen, M.; Boucreux, D.; Paranhos-Baccala, G.; Liljeström, P.; Lemmonier, F.; Inchasupé, G. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J. Gen. Virol. 2002, 83, 369-381.
32. Ip, P.P.; Boerma, A.; Regts, J.; Meijerhof, T.; Wilschut, J.; Nijman, H.V.; Daemen, T. Alphavirus-based vaccines encoding non-structural proteins of Hepatitis C virus induce robust and protective T cell responses. Mol. Ther. 2013, doi:10.1038/mt.2013.287.
33. Defang, G.N.; Khetawat, D.; Broder, C.C.; Quinnan, G.V., Jr. Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine 2010, 29, 212-220.
34. Hsu, K.F.; Hung, C.F.; Cheng, W.F.; He, L.; Slater, L.A.; Ling, M.; Wu, T.C. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 2001, 8, 376-383.
35. Cheng, W.F.; Hung, C.H.; Chai, C.Y.; Hsu, K.F.; He, L.; Ling, M.; Slater, L.A.; Roden, R.B.; Wu, T.C. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J. Virol. 2001, 75, 2368-2376.
36. Schlesinger, S.; Dubensky, T.W. Alphavirus vectors for gene expression and vaccines. Curr. Opin. Biotechnol. 1999, 10, 434-439.
37. Hariharan, M.J.; Driver, D.A.; Townsend, K.; Brumm, D.; Polo, J.M.; Belli, B.A.; Catton, D.J.; Hsu, D.; Mittelstaedt, D.; McCormack, J.E. et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J. Virol. 1998, 72, 950-958.
38. Phenix, K.V.; Wark, K.; Luke, C.J.; Skinner, M.A.; Smyth, J.A.; Mawhinney, K.A.; Todd, D. Recombinant Semliki Forest virus vector exhibits potential for avian virus vaccine development. Vaccine 2001, 19, 3116-3123.
39. Zhou, X.; Berglund, P.; Rhodes, G.; Parker, S.E.; Jondal, M.; Liljestrom, P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994, 12, 1510-1514.
40. Wolf, A.; Hodneland, K.; Frost, P.; Braaen, S.; Rimstad, E. A hemagglutinin-esterase-expressing salmonid alphavirus replicon protects Atlantic salmon (Salmo salar) against infectious salmon anemia (ISA). Vaccine 2013, 31, 661-669.
41. Pugachev, K.V.; Mason, P.W.; Shope, R.E.; Frey, T.K. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology 1995, 212, 587-594.
42. Pushko, P.; Parker, M.; Ludwig, G.V.; Davis, N.L.; Johnston, R.E.; Smith, J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239, 389-401.
43. Fleeton, M.N.; Liljeström, P.; Sheahan, B.J.; Atkins, G.J. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J. Gen. Virol. 2000, 81, 749-758.
44. Morris-Downes, M.M.; Phenix, K.V.; Smyth, J.; Sheahan, B.J.; Lileqvist, S.; Mooney, D.A.; Liljestrom, P.; Todd, D.; Atkins, G.J. Semliki Forest virus-based vaccines: Persistence, distribution and pathological analysis in two animal systems. Vaccine 2001, 19, 1978-1988.
45. Hevey, M.; Negley, D.; VanderZanden, L.; Tammariello, R.F.; Geisbert, J.; Smalljohn, C.; Smith, J.F.; Jahrling, P.B.; Smalljohn, A.L. Marburg virus vaccines: Comparing classical and new approaches. Vaccine 2001, 20, 586-593.
46. Hevey, M.; Negley, D.; Pushko, P.; Smith, J.; Schmaljohn, A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998, 251, 28-37.
47. Pasetti, M.F.; Ramirez, K.; Resendiz-Albor, A.; Ulmer, J.; Barry, E.M.; Levine, M.M. Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: Relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunity. J. Virol. 2009, 83, 2789-2794.
48. Pan, C.H.; Greer, C.E.; Hauer, D.; Legg, H.S.; Lee, E.Y.; Bergen, M.J.; Lau, B.; Adams, R.J.; Polo, J.M.; Griffin, D.E. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J. Virol. 2010, 84, 3798-3807.
49. Colombage, G.; Hall, R.; Pavy, M.; Lobigs, M. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 1998, 250, 151-163.
50. Harrington, P.R.; Yount, B.; Johnston, R.E.; Davis, N.; Moe, C.; Baris, R.S. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J. Virol. 2002, 76, 730-742.
51. Saxena, S.; Dahiya, S.S.; Sonwane, A.A.; Patel, C.L.; Saini, M.; Rai, A.; Gupta, P.K. A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge. Vaccine 2008, 26, 6592-6601.
52. Fleeton, M.N.; Chen, M.; Berglund, P.; Rhodes, G.; Parker, S.E.; Murphy, M.; Atkins, G.J. Liljestrom, P. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J. Infect. Dis. 2001, 183, 1395-1398.
53. Chen, M.; Hu, K.F.; Rozell, B.; Orvell, C.; Morein, B.; Liljestrom, P. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J. Immunol. 2002, 169, 3208-3216.
54. Bhardwaj, N.; Heise, M.T.; Ross, T.M. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl. Trop. Dis. 2010, 4, e725.
55. Sheahan, T.; Whitmore, A.; Long, K.; Ferris, M.; Rockx, B.; Funkhouser, W.; Donaldson, E.; Gralinski, L., Collier, M.; Heise, M. et al. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J. Virol. 2011, 85, 217-230.
56. Kamrud, K.I.; Hooper, J.W.; Elgh, F.; Schmaljohn, C.S. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters. Virology 1999, 263, 209-219.
57. Berglund, P.; Quesada-Rolander, M.; Putkonen, P.; Biberfeld, G.; Thorstensson, R.; Liljestrom, P. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retroviruses 1997, 13, 1487-1495.
58. Herbert, A.S.; Kuehne, A.I.; Barth, J.F.; Ortiz, R.A.; Nichols, D.K.; Zak, S.E.; Stonier, S.W.; Muhammad, M.A.; Bakken, R.R.; Prugar, L.I. et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J. Virol. 2013, 87, 4952-4964.
59. Hooper, J.W.; Ferro, A.M.; Golden, J.W.; Silvera, P.; Dudek, J.; Alterson, K.; Custer, M.; Rivers, B.; Morris, J.; Owens, G. et al. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 2009, 28, 494-511.
60. Yang, S.G.; Wo, J.E.; Li, M.W.; Mi, F.F.; Yu, C.B.; Lv, G.L.; Cao, H.C.; Lu, H.F.; Wang, B.H.; Zhu, H. et al. Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1). Vaccine 2009, 27, 7451-7458.
61. Xu, R.; Srivastava, I.K.; Greer, C.E.; Zarkikh, I.; Kraft, Z.; Kuller, L.; Polo, J.M.; Barnett, S.W.; Stamatatos, L. Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res. Hum. Retroviruses 2006, 22, 1022-1030.
62. Barnett, S.W.; Burke, B.; Sun, Y.; Kan, E.; Legg, H.; Lian, Y.; Bost, K.; Zhou, F.; Goodsell, A.; Zur M. J.; et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 2010, 84, 5975-6585.
63. Wu, Q.; Xu, F.; Fang, L.; Xu, J.; Li, B.; Jiang, Y.; Chen, H.; Xiao, S. Enhanced immunogenicity induced by an alphavirus replicon-based pseudotyped baculovirus vaccine against porcine reproductive and respiratory syndrome virus. J. Virol. Methods 2013, 187, 251-258.
64. Wolf, A.; Hodneland, K.; Frost, P.; Hoeijmakers, M.; Rimstad, E. Salmonid alphavirus-based replicon vaccine against infectious salmon anemia (ISA): Impact on infectious route and interactions of the replicon vector. Fish Shellfish Immunol. 2014, 36, 383-392.
65. Xu, C.; Mutoloki, S.; Evensen, O. Superior protection against conferred by inactivated whole virus vaccine over subunit and DNA vaccines against salmonid alphavirus infection in Atlantic salmon (Salmon salar L). Vaccine 2012, 30, 3918-3928.
66. Andersson, C.; Vasconcelos, N.M.; Sievertzon, M.; Haddad, D.; Liljeqvist, S. Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparum antigen Pf332. Scand. J. Immunol. 2001, 54, 117-124.
67. Kirman, J.R.; Turon, T.; Su, H.; Li, A.; Kraus, C.; Polo, J.M.; Belisle, J.; Morris, S.; Seder, R.A. Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect. Immun. 2003, 71, 575-579.
68. Li, N.; Yu, Y.Z.; Yu, W.Y.; Sun, Z.W. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant. Immunopharmacol. Immunotoxicol. 2011, 33, 211-219.
69. Cabrera, A.; Sáez, D.; Céspedes, S.; Andrews, E.; Oñate, A. Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice. Immunobiology 2009, 214, 467-474.
70. Thomas, J.M.; Moen, S.T.; Gnade, B.T.; Vargas-Inchaustegui, D.A.; Foltz, S.M.; Suarez, G.; Heidner, H.W.; König, R.; Chopra, A.K.; Peterson, J.W. Recombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxacin. Clin. Vaccine Immunol. 2009, 16, 1696-1699.
71. Tsuji, M.; Bergmann, C.C.; Takita-Sonoda, Y.; Murata, K.; Rodrigues, E.G.; Nussenzweig, R.S.; Zavala, F. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J. Virol. 1998, 72, 6907-6910.
72. Krasemann, S.; Jürgens, T.; Bodemer, W. Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy. J. Biotechnol. 1999, 73, 119-129.
73. Lee, J.S.; Dyas, B.K.; Nystrom, S.S.; Lind, C.M.; Smith, J.F.; Ullrich, R.G. Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon. J. Infect. Dis. 2002, 185, 1192-1196.
74. Ying, H.; Zaks, T.Z.; Wang, R.F.; Irvine, K.R.; Kammula, U.S.; Marincola, F.M.; Leitner, W.W.; Restifo, N.P. Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 1999, 5, 823-827.
75. Leitner, W.W.; Hwang, L.N.; deVeer, M.J.; Zhou, A.; Silverman, R.H.; Williams, B.R.; Dubensky, T.B.; Ying, H.; Restifo, N.P. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 2003, 9, 33-39.
76. Avogadri, F.; Merghoub, T.; Maughan, M.F.; Hirschhorn-Cymerman, D.; Morris, J.; Ritter, E.; Olmsted, R.; Houghton, A.N.; Wolchok, J.D. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One 2010, 5, e12670.
77. Yamanaka, R.; Zullo, S.A.; Ramsey, J.; Yajima, N.; Tsuchiya, N.; Tanaka, R.; Blaese, M.; Xanthopoulos, K.G. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J. Neurosurg. 2002, 97, 611-618.
78. Yamanaka, R.; Zullo, S.A.; Ramsey, J.; Onodera, M.; Tanaka, R.; Blaese, M.; Xanthopoulos, K.G. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther. 2001, 8, 796-802.
79. Yamanaka, R.; Zullo, S.A.; Tanaka, R.; Blaese, M.; Xanthopoulos, K.G. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J. Neurosurg. 2001, 94, 474-481.
80. Yamanaka, R.; Xanthopoulos, K.G. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18. DNA Cell Biol. 2005, 24, 317-324.
81. Lachman, L.B.; Rao, X.M.; Kremer, R.H.; Ozpolat, B.; Kiriakova, G.; Price, J.E. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther. 2001, 8, 259-268.
82. Wang, X.; Wang, J.P.; Rao, X.M.; Price, J.E.; Zhou, H.S.; Lachman, L.B. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice. Breast Cancer Res. 2005, 7, R580-R588.
83. Eralp, Y.; Wang, X.; Wang, J.P.; Maughan, M.F.; Polo, J.M.; Lachman, L.B. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004, 6, R275-R283.
84. Laust, A.K.; Sur, B.W.; Wang, K.; Hubby, B.; Smith, J.F.; Nelson, E.L. VRP immunotherapy targeting neu: Treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model. Breast Cancer Res. Treat. 2007, 106, 371-382.
85. Moran, T.P.; Burgents, J.E.; Long, B.; Ferrer, I.; Jaffee, E.M.; Tisch, R.M.; Johnston, R.E.; Serody, J.S. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine 2007, 25, 6604-6612.
86. Daemen, T.; Regts, J.; Holtrop, M.; Wilschut, J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther. 2002, 9, 85-94.
87. Daemen, T.; Riezebos-Brilman, A.; Regts, J.; Dontje, B.; van der Zee, A.; Wilschut, J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: Effects of the route of immunization. Antivir. Ther. 2004, 9, 733-742.
88. Cheng, W.F.; Lee, C.N.; Su, Y.N.; Chai, C.Y.; Chang, M.C.; Polo, J.M.; Hung, C.F.; Wu, T.C.; Hsieh, C.Y.; Chen, C.A. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. Cancer Gene Ther. 2006, 13, 873-885.
89. Velders, M.P.; McElhiney, S.; Cassetti, M.C.; Eiben, G.L.; Higgins, T.; Kovacs, G.R.; Elmishad, A.G.; Kast, W.M.; Smith, L.R. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 2001, 61, 7861-7867.
90. Riezebos-Brilman, A.; Regts, J.; Chen, M.; Wilschut, J.; Daemen, T. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. Vaccine 2009, 27, 701-707.
91. Cheng, W.F.; Hung, C.F.; Hsu, K.F.; Chai, C.Y.; He, L.; Polo, J.M.; Slater, L.A.; Ling, M.; Wu, T.C. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum. Gene Ther. 2002, 13, 553-568.
92. Smyth, J.W.; Fleeton, M.N.; Sheahan, B.J.; Atkins, G.J. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Ther. 2005, 12, 147-159.
93. Lyons, J.A.; Sheahan, B.J.; Galbraith, S.E.; Mehra, R.; Atkins, G.J.; Fleeton, M.N. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther. 2007, 14, 503-513.
94. Yamanaka, R.; Zullo, S.A.; Tanaka, R.; Ramsey, J.; Blaese, M.; Xanthopoulos, K.G. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg. Focus 2000, 9, e7.
95. Lundstrom, K. Biology and application of alphaviruses in gene therapy. Gene Ther. 2005, 12, S92-S97.
96. Quetglas, J.I.; Dubrot, J.; Bezunartea, J.; Sanmamed, M.F.; Hervas-Stubbs, S.; Smerdou, C.; Melero, I. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol. Ther. 2012, 20, 1664-1675
97. Leslie, M.C.; Zhao, Y.J.; Lachman, L.B.; Hwu, P.; Wu, G.J.; Bar-Eli, M. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther. 2007, 14, 316-323.
98. Morse, M.A.; Hobeika, A.C.; Osada, T.; Berglund, P.; Hubby, B.; Negri, S.; Niedzwiecki, G.; Devi G.R.; Burnett, G.K.; Clay, T.M. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J. Clin. Invest. 2010, 120, 3234-3241.
99. Slovin, S.F.; Kehoe, M.; Durso, R.; Fernandez, C.; Olson, W.; Gao, J.P.; Israel, R.; Sher, H.I.; Morris, S. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 2013, 31, 943-949.
100. Durso, R.J.; Andjelic, S.; Gardner, J.P.; Margitich, D.J.; Donovan, G.P.; Arrigale, R.R.; Wang, X.; Maughan, M.F.; Talarico, T.L.; Olmsted, R.A. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin. Cancer Res. 2007, 13, 3999-4008.
101. Garcia-Hernandez, M.L.; Gray, A.; Hubby, B.; Kast, W.M. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: A candidate antigen for treating prostate cancer. Cancer Res. 2007, 67, 1344-1351.
102. Garcia-Hernandez, M.L.; Gray, A.; Hubby, B.; Klinger, O.J.; Kast, WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008, 68, 861-869.
103. Colmenero, P.; Chen, M.; Castaños-Velez, E.; Liljeström, P.; Jondal, M. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int. J. Cancer 2002, 98, 554-560.
104. Ying, H.; Zeng, G.; Black, K.L. Innovative cancer vaccine strategies based on the identification of tumour-associated antigens. BioDrugs 2001, 15, 819-831.
105. Colmenero, P.; Liljeström, P.; Jondal, M. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther. 1999, 6, 1728-1733.
106. Leitner, W.W.; Ying, H.; Driver, D.A.; Dubensky, T.W.; Restifo, N.P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 2000, 60, 51-55.
107. Daemen, T.; Pries, F.; Bungener, L.; Kraak, M.; Regts, J.; Wilschut, J. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther. 2000, 7, 1859-1866.
108. Cheng, W.F.; Hung, C.F.; Hsu, K.F.; Chai, C.Y.; He, L.; Ling, M.; Slater, L.A.; Roden, R.B.; Wu, T.C. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum. Gene Ther. 2001, 12, 235-252.
109. Eiben, G.L.; Velders, M.P.; Schreiber, H.; Cassetti, M.C.; Pullen, J.K.; Smith, L.R.; Kast, W.M. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res. 2002, 62, 5792-5799.
110. Cassetti, M.C.; McElhiney, S.P.; Shahabi, V.; Pullen, J.K.; Le, Poole, I.; Eiben, G.L.; Smith, L.R.; Kast, W.M. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004, 22, 520-527.
111. Yamanaka, R.; Tsuchiya, N.; Yajima, N.; Honma, J.; Hasegawa, H.; Tanaka, R.; Ramsey, J.; Blaese, R.M.; Xanthopoulos, K.G. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J. Neurosurg. 2003, 99, 746-753.
112. Bennett, A.M.; Elvin, S.J.; Wright, A.J.; Jones, S.M.; Phillpotts, R.J. An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine 2000, 19, 337-347.
113. Hart, M.K.; Caswell-Stephan, K.; Bakken, R.; Tammariello, R.; Pratt, W.; Davis, N.; Johnston, R.E.; Smith, J.; Steele, K. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 2000, 18, 3067-3075.
114. Schoepp, R.J.; Smith, J.F.; Parker, M.D. Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates. Virology 2002, 302, 299-309.
115. Edelman, R.; Tacket, C.O.; Wasserman, S.S.; Bodison, S.A.; Perry, J.G.; Mangiafico, J.A. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 2000, 62, 681-685.
116. Mallilankaraman, K.; Shedlock, D.J.; Bao, H.; Kawalekar, O.U.; Fagone, P.; Ramanathan, A.A.; Ferraro, B. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl. Trop. Dis. 2011, 5, e928.
117. Kim, D.Y.; Atasheva, S.; Foy, N.J.; Wang, E.; Frolova, E.I.; Weaver, S.; Frolov, I. Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype. J. Virol. 2011, 85, 4363-4376.
118. Kramer, R.M.; Zeng, Y.; Sahni, N.; Kueltzo, L.A.; Schwartz, R.M.; Srivastava, I.K.; Crane, L.; Joshi, S.B.; Volkin, D.B.; Middaugh, C.R. Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions. J. Pharm. Sci. 2013, 102, 4305-4314.
119. Dash, P.K.; Tiwari, M.; Santhosh, S.R.; Parida, M.; Lakshmana Rao, P.V. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem. Biophys. Res. Commun. 2008, 376, 718-722.
120. Kamrud, K.I.; Coffield, V.M.; Owens, G.; Goodman, C.; Alterson, K.; Custer, M.; Murphy, M.A.; Lewis, W.; Timberlake, S.; Wansley, E.K. In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs. J. Virol. 2010, 84, 7713-7725.
121. Elvin, S.J.; Bennett, A.M.; Phillpotts, R.J. Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus. J. Med. Virol. 2002, 67, 384-393.
122. Dupuy, L.C.; Richards, M.J.; Reed, D.S.; Schmaljohn, C.S. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine 2010, 28, 7345-7350.
123. Darwin, J.R.; Kenney, J.L.; Weaver, S.C. Transmission potential of two chimeric Chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus. Am. J. Trop. Med. Hyg. 2011, 84, 1012-1015.
124. Bhomia, M.; Sharma, A.; Gayen, M.; Gupta, P.; Maheshwari, R.K. Artificial microRNAs can effectively inhibit replication of Venezuelan equine encephalitis virus. Antivir. Res. 2013, 100, 429-434.
125. Prow, T.W.; Chen, X.; Prow, N.A.; Fernando, G.J.; Tan, C.S.; Raphael, A.P.; Chang, D.; Ruutu, M.D.; Jenkins, D.W.; Pyke, A. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 2010, 6, 1776-1784.
126. Berglund, P.; Sjöberg, M.; Garoff, H.; Atkins, G.J.; Sheahan, B.J.; Liljestrom, P. Semliki Forest virus expression system: Production of conditionally infectious recombinant particles. Biotechnology 1993, 11, 916-920.